Andrew Spokes
Farallon Capital · Investor
AUM (13F)
$16.8B
# of Holdings
165
3Y performance ⓘ
—
vs S&P 500 ⓘ
—
Updated
Mar 31
Andrew Spokes's Farallon Capital holds 165 U.S.-equity positions worth $16.8B (SEC 13F, Q1 2026). Top positions: State Str Spdr S&p 500 Etf T 8.5%, Revolution Medicines, Inc. Common Stock 7.5%, Amazon.Com Inc 5.0%.
Holdings
| Stock | % of portfolio | Shares | Value | Latest activity | Avg buy price | Current price | Date |
|---|---|---|---|---|---|---|---|
| SPY PUT State Str Spdr S&p 500 Etf T | 8.5% | 2.3M | $1.5B | NEW PUT (+2.3M) | — | — | 2026-03-31 |
| RVMD Revolution Medicines, Inc. Common Stock | 7.5% | 13.6M | $1.3B | NEW (+13.6M) | $97.25 | $165.81 (+70%) | 2026-03-31 |
| AMZN Amazon.Com Inc | 5.0% | 4.2M | $879M | NEW (+4.2M) | $208.27 | $232.79 (+12%) | 2026-03-31 |
| MSFT MICROSOFT CORP | 5.0% | 2.3M | $868M | NEW (+2.3M) | $370.17 | $367.34 (−1%) | 2026-03-31 |
| AON Aon plc Class A | 4.6% | 2.5M | $811M | NEW (+2.5M) | $322.78 | $313.63 (−3%) | 2026-03-31 |
| BBIO BridgeBio Pharma, Inc. Common Stock | 4.0% | 9.4M | $695M | NEW (+9.4M) | $74.26 | $68.92 (−7%) | 2026-03-31 |
| PTGX Protagonist Therapeutics, Inc | 3.8% | 6.3M | $669M | NEW (+6.3M) | $105.40 | $115.03 (+9%) | 2026-03-31 |
| NTRA Natera, Inc. Common Stock | 3.7% | 3.2M | $641M | NEW (+3.2M) | $199.99 | $228.80 (+14%) | 2026-03-31 |
| EXEL Exelixis Inc | 3.2% | 13.1M | $562M | NEW (+13.1M) | $42.89 | $51.35 (+20%) | 2026-03-31 |
| AVGO Broadcom Inc. Common Stock | 3.1% | 1.8M | $551M | NEW (+1.8M) | $309.51 | $392.13 (+27%) | 2026-03-31 |
| UNH UNITEDHEALTH GROUP INCORPORATED (Delaware) | 2.8% | 1.8M | $493M | NEW (+1.8M) | $270.59 | $406.68 (+50%) | 2026-03-31 |
| SNPS Synopsys Inc | 2.7% | 1.2M | $481M | NEW (+1.2M) | $396.48 | $464.58 (+17%) | 2026-03-31 |
| BSX Boston Scientific Corp. | 2.7% | 7.5M | $469M | NEW (+7.5M) | $62.75 | $44.33 (−29%) | 2026-03-31 |
| TMO Thermo Fisher Scientific, Inc. | 2.5% | 881K | $433M | NEW (+881K) | $491.53 | $464.01 (−6%) | 2026-03-31 |
| KKR KKR & Co. Inc. | 2.5% | 4.7M | $432M | NEW (+4.7M) | $92.50 | $96.90 (+5%) | 2026-03-31 |
| LNTH Lantheus Holdings, Inc | 2.4% | 5.6M | $424M | NEW (+5.6M) | $75.85 | $106.20 (+40%) | 2026-03-31 |
| WAB Wabtec Inc. | 2.3% | 1.6M | $402M | NEW (+1.6M) | $249.91 | $276.75 (+11%) | 2026-03-31 |
| SCHW The Charles Schwab Corporation | 2.1% | 4.0M | $372M | NEW (+4.0M) | $93.98 | $92.03 (−2%) | 2026-03-31 |
| LQDA Liquidia Corporation Common Stock | 1.9% | 8.7M | $327M | NEW (+8.7M) | $37.74 | $75.49 (+100%) | 2026-03-31 |
| CRNX Crinetics Pharmaceuticals, Inc. | 1.7% | 8.3M | $303M | NEW (+8.3M) | $36.32 | $35.38 (−3%) | 2026-03-31 |
| GOOG Alphabet Inc. Class C Capital Stock | 1.6% | 996K | $286M | NEW (+996K) | $286.86 | $348.78 (+22%) | 2026-03-31 |
| ROIV Roivant Sciences Ltd. Common Shares | 1.5% | 9.7M | $268M | NEW (+9.7M) | $27.70 | $31.25 (+13%) | 2026-03-31 |
| V VISA Inc. | 1.4% | 841K | $254M | NEW (+841K) | $302.24 | $326.60 (+8%) | 2026-03-31 |
| ARMK ARAMARK | 1.4% | 6.1M | $249M | NEW (+6.1M) | $40.54 | $53.55 (+32%) | 2026-03-31 |
| BEAM Beam Therapeutics Inc. Common Stock | 1.4% | 10.1M | $242M | NEW (+10.1M) | $23.83 | $35.53 (+49%) | 2026-03-31 |
| DIS The Walt Disney Company | 1.3% | 2.4M | $231M | NEW (+2.4M) | $96.38 | $102.45 (+6%) | 2026-03-31 |
| MA Mastercard Incorporated | 1.2% | 435K | $217M | NEW (+435K) | $499.66 | $484.09 (−3%) | 2026-03-31 |
| MCK McKesson Corporation | 1.2% | 234K | $203M | NEW (+234K) | $865.36 | $744.85 (−14%) | 2026-03-31 |
| AGIO Agios Pharmaceuticals, Inc. | 1.1% | 5.7M | $192M | NEW (+5.7M) | $33.83 | $35.10 (+4%) | 2026-03-31 |
| CNTA Centessa Pharmaceuticals Plc | 1.1% | 4.8M | $191M | NEW (+4.8M) | $39.72 | $40.18 (+1%) | 2026-03-31 |
| TNGX Tango Therapeutics, Inc. | 1.1% | 9.1M | $190M | NEW (+9.1M) | $20.92 | $28.50 (+36%) | 2026-03-31 |
| GRAL GRAIL, Inc. Common Stock | 1.0% | 3.3M | $168M | NEW (+3.3M) | $51.68 | $62.10 (+20%) | 2026-03-31 |
| TYRA Tyra Biosciences, Inc. Common Stock | 0.8% | 3.6M | $137M | NEW (+3.6M) | $38.30 | $30.14 (−21%) | 2026-03-31 |
| THC Tenet Healthcare Corporation New | 0.5% | 452K | $85M | NEW (+452K) | $188.71 | $178.75 (−5%) | 2026-03-31 |
| CAH Cardinal Health, Inc. | 0.4% | 368K | $78M | NEW (+368K) | $211.31 | $222.74 (+5%) | 2026-03-31 |
| PCVX Vaxcyte, Inc. Common Stock | 0.4% | 1.3M | $73M | NEW (+1.3M) | $58.11 | $52.11 (−10%) | 2026-03-31 |
| DNTH Dianthus Therapeutics, Inc. Common Stock | 0.4% | 836K | $70M | NEW (+836K) | $83.92 | $87.37 (+4%) | 2026-03-31 |
| BTSG BrightSpring Health Services, Inc. Common Stock | 0.4% | 1.6M | $69M | NEW (+1.6M) | $42.61 | $67.20 (+58%) | 2026-03-31 |
| TWST Twist Bioscience Corporation Common Stock | 0.4% | 1.4M | $68M | NEW (+1.4M) | $47.52 | $85.17 (+79%) | 2026-03-31 |
| BIDU Baidu Inc | 0.3% | 444K | $49M | NEW (+444K) | $111.42 | $111.74 (+0%) | 2026-03-31 |
| CGON CG Oncology, Inc. Common stock | 0.3% | 674K | $46M | NEW (+674K) | $67.68 | $66.25 (−2%) | 2026-03-31 |
| AZN AstraZeneca PLC | 0.2% | 226K | $45M | NEW (+226K) | $197.22 | $176.43 (−11%) | 2026-03-31 |
| MRK Merck & Co., Inc. | 0.2% | 361K | $43M | NEW (+361K) | $120.29 | $115.48 (−4%) | 2026-03-31 |
| ACHC Acadia Healthcare Company, Inc. | 0.2% | 1.7M | $41M | NEW (+1.7M) | $23.39 | $25.21 (+8%) | 2026-03-31 |
| WELL Welltower Inc. | 0.2% | 200K | $40M | NEW (+200K) | $197.71 | $211.45 (+7%) | 2026-03-31 |
| IMVT Immunovant, Inc. Common Stock | 0.2% | 1.5M | $38M | NEW (+1.5M) | $24.84 | $38.10 (+53%) | 2026-03-31 |
| ENTA Enanta Pharmaceuticals, Inc | 0.2% | 2.9M | $36M | NEW (+2.9M) | $12.63 | $13.37 (+6%) | 2026-03-31 |
| JNJ Johnson & Johnson | 0.2% | 148K | $36M | NEW (+148K) | $244.44 | $231.29 (−5%) | 2026-03-31 |
| BBNX Beta Bionics, Inc. Common Stock | 0.2% | 3.6M | $36M | NEW (+3.6M) | $10.02 | $13.70 (+37%) | 2026-03-31 |
| ASMB Assembly Biosciences, Inc | 0.2% | 1.2M | $34M | NEW (+1.2M) | $27.75 | $25.15 (−9%) | 2026-03-31 |
Showing top 50 of 165 holdings by value.
FAQ ▾
What are Andrew Spokes's largest holdings?
As of the latest 13F: State Str Spdr S&p 500 Etf T 8.5%, Revolution Medicines, Inc. Common Stock 7.5%, Amazon.Com Inc 5.0%, MICROSOFT CORP 5.0%, Aon plc Class A 4.6%.
How big is Farallon Capital's 13F portfolio?
$16.8B across 165 disclosed U.S.-equity positions.
Where does this data come from?
U.S. SEC Form 13F-HR institutional holdings filings.
Sourced from SEC Form 13F-HR filings · Not investment advice ▾
Data as of 2026-03-31 · Methodology
13F-replication (price return, filing-date based) — not an audited fund return.
Published by WealthFile · Not investment advice.
Latest activity = change vs. the prior 13F. Avg buy price = est. entry over the trailing 3 years (gain = vs. latest price). Returns are 13F-replication, not audited fund returns. Sourced from SEC 13F filings.